7F7E

SARS-CoV-2 S protein RBD in complex with A5-10 Fab

7F7E の概要

• エントリーDOI: 10.2210/pdb7f7e/pdb
• 分子名称: Heavy chain of A5-10 Fab, Light chain of A5-10 Fab, Spike protein S1, ... (4 entities in total)
• 機能のキーワード: antibody, sars-cov-2, virus, viral protein
• 由来する生物種: Homo sapiens (human); 詳細
• タンパク質・核酸の鎖数: 3
• 化学式量合計: 68665.65

構造登録者

Dou, Y.,Wang, X.,Wang, K.,Liu, P.,Lu, B. (登録日: 2021-06-29, 公開日: 2022-02-02, 最終更新日: 2024-10-16)

主引用文献

Wang, F.,Li, L.,Dou, Y.,Shi, R.,Duan, X.,Liu, H.,Zhang, J.,Liu, D.,Wu, J.,He, Y.,Lan, J.,Lu, B.,Feng, H.,Yan, J.
Etesevimab in combination with JS026 neutralizing SARS-CoV-2 and its variants.
Emerg Microbes Infect, 11:548-551, 2022

PubMed Abstract: The neutralizing antibody is a potential therapeutic for the ongoing COVID-19 pandemic. As an antiviral agent, numerous mAbs recognize the epitopes that overlap with ACE2-binding sites in the SARS-CoV-2-RBD. Some studies have shown that residual changes on the spike protein can significantly decrease the efficiency of neutralizing antibodies. To address this issue, a therapeutic cocktail could be an effective countermeasure. In the present study, we isolated a fully human neutralizing antibody, JS026, from a convalescent patient. The comparative analysis revealed that JS026 binding to SARS-CoV-2-RBD mainly located between epitopes for class 2 and class 3 mAbs as opposed to that of class 1 (etesevimab) antibodies. A cocktail of etesevimab and JS026 increased neutralizing efficacy against both wild-type SARS-CoV-2 and the recent emergence of Alpha, Beta, Gamma, and Delta variants. JS026 and the cocktail reduced virus titers in the infected lungs of hACE2 transgenic mice and relieved pathological changes. These findings would benefit antibody-based therapeutic countermeasures in the treatment of COVID-19.

PubMed: 35060840
DOI: 10.1080/22221751.2022.2032374

実験手法

X-RAY DIFFRACTION (2.49 Å)